SCHEMBL32664232

SCHEMBL32664232

COC(=O)c1cc2c(O)ccnn2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.44
CA12 O43570 4/20 0.44
CA1 P00915 4/20 0.44
CA2 P00918 4/20 0.44
CA7 P43166 4/20 0.44
CA9 Q16790 4/20 0.44
CA14 Q9ULX7 4/20 0.44
XDH P47989 2/20 0.44
KDR P35968 1/20 0.43
KDM4E B2RXH2 4/20 0.42
LMNA P02545 3/20 0.42
POLB P06746 2/20 0.42
GAA P10253 2/20 0.42
NFKB1 P19838 1/20 0.42
GFER P55789 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
FUT7 Q11130 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32664196 0.84 MAPK14 (0.43) MAPK14KDRPOLBGAAL3MBTL1
SCHEMBL25283404 0.81 GAA (0.52) KDM4EPOLBGAAL3MBTL1MAP4K4
SCHEMBL17331592 0.75 ALDH1A1 (0.47) MAPK14CA12CA1CA2CA7
SCHEMBL8887061 0.73 ALDH1A1 (0.45) CA12CA1CA2CA7CA9
SCHEMBL4045312 0.72 MAPK14 (0.51) MAPK14KDRKDM4EPOLBMAP4K4
SCHEMBL24742061 0.70 MEN1 (0.38) CA12CA1CA2CA7CA9
SCHEMBL31132784 0.70 XDH (0.46) MAPK14CA12CA1CA2CA7
SCHEMBL29328556 0.70 ALDH1A1 (0.50) CA12CA1CA2CA7CA9
SCHEMBL3642134 0.69 JMJD6 (0.44) CA12CA1CA2CA7CA9
SCHEMBL25237339 0.69 HSD17B10 (0.43) KDM4ELMNAPOLBGAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022125-A1 PYRROLOPYRIDAZINE VEGFR INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022125-A1 PYRROLOPYRIDAZINE VEGFR INHIBITORS FLT1, KDR, FLT4 MAPK14 1850/4885CA12 2224/4885CA1 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.